發(fā)布時(shí)間：2019-01-12 17:37

【摘要】：現(xiàn)如今,艾滋病毒和結(jié)核病等傳染性疾病已成為嚴(yán)重影響人類(lèi)健康的公共問(wèn)題。尤其發(fā)展中國(guó)家和欠發(fā)達(dá)國(guó)家受到疾病困擾尤為嚴(yán)重。但是,藥物專(zhuān)利卻影響著藥物的可獲得性,使得藥品的價(jià)格在發(fā)展中國(guó)家和欠發(fā)達(dá)國(guó)家反而比在發(fā)達(dá)國(guó)家更高。強(qiáng)制許可的應(yīng)用雖然一定程度上緩解了上述問(wèn)題,但是同時(shí)也會(huì)引發(fā)一系列社會(huì)問(wèn)題,如發(fā)達(dá)國(guó)家專(zhuān)利藥制造商市場(chǎng)競(jìng)爭(zhēng)削弱,其利潤(rùn)降低,竟而影響其創(chuàng)新研究的動(dòng)力,相應(yīng)吸引投資能力降低、最終導(dǎo)致制藥工業(yè)水平滯后等。雖然專(zhuān)利藥制造商可以獲取一定的補(bǔ)償,但是國(guó)際也沒(méi)有統(tǒng)一的合適的標(biāo)準(zhǔn)可以參考。因此藥品研發(fā)與保證以可承受價(jià)格獲得藥品之間的沖突沒(méi)能很好地得到解決。為了解決這個(gè)沖突,本文對(duì)于發(fā)達(dá)國(guó)家專(zhuān)利藥和發(fā)展中國(guó)家制造商之間的自愿轉(zhuǎn)讓做了相關(guān)研究。在處方藥市場(chǎng)下,本文構(gòu)建了一個(gè)雙寡頭模型。我們考慮兩種創(chuàng)新方式(質(zhì)量提高型和成本降低型)和三種不同的技術(shù)轉(zhuǎn)讓合同機(jī)制(即固定費(fèi)用合同,特許權(quán)合同和兩部收費(fèi)合同),分析比較沒(méi)有發(fā)生轉(zhuǎn)讓的市場(chǎng)和不同轉(zhuǎn)讓合同下的市場(chǎng)中發(fā)達(dá)國(guó)家專(zhuān)利藥生產(chǎn)商家以及本土生產(chǎn)普通藥生產(chǎn)企業(yè)的利潤(rùn),分析每一種創(chuàng)新方式下的每一種轉(zhuǎn)讓合同實(shí)施要滿(mǎn)足的條件,以及發(fā)達(dá)國(guó)家專(zhuān)利藥生產(chǎn)商家的最優(yōu)決策和最優(yōu)利潤(rùn)。同時(shí)對(duì)進(jìn)口國(guó)的病人剩余和社會(huì)福利的相關(guān)情況進(jìn)分析,并對(duì)強(qiáng)制許可的補(bǔ)償標(biāo)準(zhǔn)提供一個(gè)合理的參考。通過(guò)本文研究發(fā)現(xiàn):產(chǎn)品差異化和醫(yī)生代理行為對(duì)發(fā)達(dá)國(guó)家企業(yè)的技術(shù)轉(zhuǎn)讓決策有很大的影響。(1)在質(zhì)量提高型以及成本降低的非重大創(chuàng)新情況下,當(dāng)技術(shù)創(chuàng)新相對(duì)不高時(shí),發(fā)達(dá)國(guó)家制造商可以采用任何合同機(jī)制來(lái)發(fā)生技術(shù)轉(zhuǎn)讓。(2)在使用不同的技術(shù)轉(zhuǎn)讓合同時(shí),我們發(fā)現(xiàn)只要發(fā)生固定費(fèi)用,特許權(quán)使用費(fèi)和兩部收費(fèi)合同,就可以增加患者剩余,但專(zhuān)利權(quán)合同和兩部收費(fèi)合同可能會(huì)減少進(jìn)口國(guó)的社會(huì)福利。(3)若創(chuàng)新類(lèi)型為質(zhì)量提高型,在一定條件下,兩部收費(fèi)合同同將等于固定費(fèi)用或特許權(quán)使用費(fèi)合同。若創(chuàng)新類(lèi)型為成本降低型,在一定條件下,兩部收費(fèi)合同同將等于固定費(fèi)用。(4)在成本降低的重大創(chuàng)新情況下,與以往文獻(xiàn)結(jié)論很不一樣,傳統(tǒng)文獻(xiàn)認(rèn)為由于重大創(chuàng)新造成壟斷而不愿意再發(fā)生技術(shù)轉(zhuǎn)讓,現(xiàn)在發(fā)現(xiàn)由于醫(yī)生代理行為的差異,使得發(fā)達(dá)國(guó)家制造商在一定條件下也愿意進(jìn)行技術(shù)授權(quán)。本文研究結(jié)論對(duì)發(fā)達(dá)國(guó)家制造商的最優(yōu)轉(zhuǎn)讓策略的選擇,和發(fā)展中國(guó)家合理引進(jìn)先進(jìn)技術(shù),以及相關(guān)政策的制定和完善都具有很重要的管理啟示意義和政策含義。
[Abstract]:Nowadays, infectious diseases such as HIV and tuberculosis have become a serious public problem affecting human health. In particular, developing countries and less developed countries suffer from the disease is particularly serious. However, drug patents affect the availability of drugs, making drug prices higher in developing and less developed countries than in developed countries. Although the application of compulsory licensing alleviates the above problems to some extent, it will also lead to a series of social problems, such as the weakening of market competition and the decline of profits of patent drug manufacturers in developed countries, thus affecting the impetus for innovation and research. Accordingly, the ability to attract investment is reduced, resulting in the level of pharmaceutical industry lagging behind and so on. Although patented drug manufacturers can get some compensation, there is no uniform international standard to refer to. Therefore, the conflict between drug development and guaranteed access to drugs at affordable prices has not been well resolved. In order to resolve this conflict, this paper studies the voluntary transfer of patent drugs between developed countries and manufacturers in developing countries. In the prescription drug market, this paper constructs a duopoly model. We consider two innovative approaches (quality improvement and cost reduction) and three different mechanisms for technology transfer contracts (i.e. fixed cost contracts, concession contracts and two fee contracts), Analyzing and comparing the profits of the developed countries' patent drug producers and local producers of common medicines in the markets where there is no transfer and markets under different transfer contracts. This paper analyzes the conditions to be satisfied in the implementation of each transfer contract under each innovative mode, and the optimal decision and profit of the patent pharmaceutical manufacturers in developed countries. At the same time, the author analyzes the patient surplus and social welfare in importing country, and provides a reasonable reference to the compensation standard of compulsory license. In this paper, we find that product differentiation and doctor-agent behavior have great influence on the technology transfer decision of developed country enterprises. (1) in the case of non-significant innovation of quality improvement and cost reduction, When technological innovation is relatively low, manufacturers in developed countries can use any contractual mechanism to transfer technology. (2) when using different technology transfer contracts, we find that as long as there is a fixed cost, Royalties and two fee contracts can increase patient surplus, but patent contracts and two fee contracts may reduce social welfare in importing countries. (3) if the innovation type is quality-enhancing, under certain conditions, Both fee contracts will be equal to fixed fees or royalties contracts. If the innovation type is cost reduction, under certain conditions, the two fee contracts will be equal to the fixed cost. (4) in the case of significant innovation with lower cost, it is very different from the previous literature conclusion. Traditional literature holds that technology transfer is unwilling to occur because of monopoly caused by major innovation. Now it is found that due to the difference of doctors' agency behavior, manufacturers in developed countries are willing to license technology under certain conditions. The conclusion of this paper is of great significance to the choice of optimal transfer strategy for manufacturers in developed countries, the reasonable introduction of advanced technology to developing countries, and the formulation and improvement of relevant policies.
【學(xué)位授予單位】：中國(guó)科學(xué)技術(shù)大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：F416.72;F713.584

【參考文獻(xiàn)】

相關(guān)期刊論文 前6條

1 喬羽;褚淑貞;;我國(guó)藥品技術(shù)轉(zhuǎn)讓中存在的問(wèn)題及對(duì)策研究[J];上海醫(yī)藥;2014年13期

2 曹曉瑞;畢軍;黃民;;國(guó)內(nèi)外藥品技術(shù)轉(zhuǎn)讓相關(guān)制度對(duì)比簡(jiǎn)析[J];中國(guó)醫(yī)藥工業(yè)雜志;2014年05期

3 李長(zhǎng)英;王君美;;最優(yōu)技術(shù)授權(quán)及其社會(huì)福利分析[J];世界經(jīng)濟(jì);2010年01期

4 李長(zhǎng)英;王君美;;技術(shù)授權(quán)形式及其社會(huì)福利效應(yīng)[J];世界經(jīng)濟(jì)文匯;2009年06期

5 張?jiān)i;科技創(chuàng)新與最優(yōu)專(zhuān)利轉(zhuǎn)讓方式的選擇問(wèn)題[J];經(jīng)濟(jì)科學(xué);2005年02期

6 謝申祥;張輝;王孝松;;外國(guó)企業(yè)的技術(shù)授權(quán)策略與社會(huì)福利[J];世界經(jīng)濟(jì);2013年10期

相關(guān)碩士學(xué)位論文 前4條

1 張迪;藥品技術(shù)轉(zhuǎn)讓的研究[D];成都中醫(yī)藥大學(xué);2015年

2 張艷;論藥品專(zhuān)利強(qiáng)制許可制度[D];山東大學(xué);2015年

3 嚴(yán)立;制藥業(yè)的專(zhuān)利法律問(wèn)題研究[D];復(fù)旦大學(xué);2009年

4 劉若昕;專(zhuān)利藥品的平行進(jìn)口、強(qiáng)制許可與差別定價(jià)[D];吉林大學(xué);2005年

，

本文編號(hào)：2408029